Creator: Medtronic
Medical device maker Medtronic beat analysts’ estimates for quarterly profit and raised its full-year earnings prognostication for the second time on Tuesday, boosted by strong performance in its unit that makes surgical instruments.
The world’s as a wholest standalone medical device maker has been beefing up its minimally invasive and robotic surgery device businesses via acquisitions to make up for slowing growth in its top-earning unit that makes stents and heart pumps.
The minimally invasive therapies task, which makes surgical instruments and endoscopy products, brought in revenue of $2.14 billion, ahead of analysts’ normal estimate of $2.13 billion, according to IBES data from Refinitiv.
But its cardiac and vascular unit missed beliefs for revenue. The business reported revenue of $2.86 billion, while analysts had expected $2.87 billion.
Net sales make it 3% to $7.71 billion, beating estimates of $7.66 billion.
Net income attributable to the company rose to $1.36 billion, or $1.01 per interest, in the second quarter ended Oct. 25, from $1.12 billion, or 82 cents per share, a year earlier.
Excluding fillers, the company earned $1.31 per share, topping analysts’ average estimate of $1.28.
Medtronic said it now expects 2020 set profit to be in the range of $5.57 to $5.63 per share, up from the prior forecast of $5.54 to $5.60.
Analysts were expecting full-year earnings of $5.56 per allocation.